1. Schizophrenia and the dopamine-β-hydroxylase gene
- Author
-
T. Füreder, K. Meszaros, N. Fathi, E. Resinger, V. Pfersmann, E. Miller-Reiter, Thomas Stompe, Werner Sieghart, Angela Heiden, Elisabeth Lenzinger, H.N. Aschauer, Kurt Hornik, Siegfried Kasper, Ulrike Willinger, E. Gerhard, and Karoline Fuchs
- Subjects
Male ,Candidate gene ,Molecular Sequence Data ,Chromosome 9 ,Dopamine beta-Hydroxylase ,Biology ,Polymerase Chain Reaction ,behavioral disciplines and activities ,Norepinephrine ,Dopamine ,mental disorders ,Genetics ,medicine ,Humans ,Computer Simulation ,Allele ,Alleles ,Biological Psychiatry ,Genetics (clinical) ,ABL ,Base Sequence ,Models, Genetic ,medicine.disease ,Pedigree ,Psychiatry and Mental health ,Genetic marker ,Schizophrenia ,Austria ,Female ,Lod Score ,Chromosomes, Human, Pair 9 ,medicine.drug - Abstract
Alterations in dopamine neurotransmission and disturbed norepinephrine activity have been implicated in the pathogenesis of schizophrenia. We considered the dopamine-beta-hydroxylase (DBH) gene located on the long arm of chromosome 9 (9q34.3) as a candidate gene for schizophrenia. DBH catalyzes the synthesis of norepinephrine from dopamine in noradrenergic neurons. In addition to DBH we used in the linkage study DNA markers ABL (centromeric) and D9S114 (telomeric). The aim of this study was to test linkage and association between PCR-based genotyped markers and schizophrenia. A simulation was done to investigate the power of our sample. In 34 Austrian families we could not detect linkage between schizophrenia and schizophrenia spectrum disorders and the three genetic markers. We could not find any significant deviation in allelic or genotypic distribution from expectations. Based on our results we conclude that the DBH gene seems to have no strong contribution in the etiology of schizophrenia.
- Published
- 1996
- Full Text
- View/download PDF